drugset / Trial / NCT02954848

Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)

NCT02954848

Phase 3 Completed 484 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of oral TAK-438 10 mg once-daily in the treatment of non-erosive gastroesophageal reflux disease (NERD).

Timeline

Start
2016-11-15
Primary completion
2018-02-25
Completion
2018-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Vonoprazan Other / unclassified 10 mg Oral